Alpha Cognition (NASDAQ:ACOG) Announces Earnings Results, Misses Estimates By $0.01 EPS

Alpha Cognition (NASDAQ:ACOG) announced its earnings results on Wednesday. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01), reports. The firm had revenue of $7.78 million for the quarter, compared to the consensus estimate of $7.04 million. Alpha Cognition had a negative return on equity of 54.60% and a negative net margin of 153.61%.

Here are the key takeaways from Alpha Cognition’s conference call:

• ZUNVEYL generated $7.8 million in Q3 net product revenue, up approximately 30% sequentially, with filled prescriptions up about 31%. Prescriber and facility adoption also grew, and the company exceeded its original full-year prescriber goal one quarter early.
• Commercial productivity improved as more than half of targeted prescribers wrote ZUNVEYL in Q3, repeat prescribing increased, and average prescriptions per writer rose to about seven. Management says growth is coming from both new customers and deeper use among existing prescribers.
• Formulary coverage was unchanged from prior quarters, and management does not expect a formulary win before year-end, though it hopes for traction early in 2027. The company says prior authorizations remain a friction point, even as its team reports a 95% approval rate when it supports the process.
• Management reiterated its goal of operating profitability in 2027, citing revenue growth outpacing spending, essentially flat sequential operating expenses, and $37.8 million in cash with no debt. It reaffirmed 2026 operating-expense guidance of $50 million–$54 million but did not provide revenue guidance.
• The company highlighted early real-world evidence showing higher therapeutic-dose attainment and fewer medication classes among ZUNVEYL residents, while noting that additional CONVERGE updates and publication are expected in 2027. A sublingual-formulation PK study was inconclusive, prompting another study planned for early 2027.

Alpha Cognition Trading Down 1.3%

ACOG opened at $8.62 on Thursday. Alpha Cognition has a 1-year low of $4.50 and a 1-year high of $10.14. The company has a market cap of $187.73 million, a P/E ratio of -7.84 and a beta of 2.32. The company has a fifty day moving average price of $8.77 and a two-hundred day moving average price of $7.26.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. HC Wainwright upped their price target on shares of Alpha Cognition from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Monday, August 17th. B. Riley Financial initiated coverage on Alpha Cognition in a research report on Thursday, August 20th. They issued a “buy” rating and a $21.00 price objective for the company. Craig Hallum restated a “buy” rating and set a $17.00 target price on shares of Alpha Cognition in a research report on Friday, August 14th. Finally, Wall Street Zen upgraded Alpha Cognition from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Five investment analysts have rated the stock with a Buy rating. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $18.00.

Insider Buying and Selling at Alpha Cognition

In related news, Director Robert Wills acquired 10,000 shares of the business’s stock in a transaction dated Friday, August 21st. The shares were bought at an average price of $9.62 per share, with a total value of $96,200.00. Following the transaction, the director directly owned 32,241 shares of the company’s stock, valued at $310,158.42. This trade represents a 44.96% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 8.60% of the company’s stock.

About Alpha Cognition

Alpha Cognition Inc. is a biopharmaceutical company focused on developing and commercializing treatments for neurodegenerative diseases and cognitive disorders. The company’s work is centered on therapies intended to address the medical needs of patients with Alzheimer’s disease and other conditions affecting cognition. Its lead commercial product is ZUNOVO (galantamine hydrobromide) extended-release capsules, an orally administered treatment approved by the U.S. Food and Drug Administration for mild-to-moderate dementia of the Alzheimer’s type.